Pharma and Life Science Specialist Novartis Provides 30,000 Employees With Over 500 Qlik Sense Apps For Data-Driven Business Processes
Philadelphia – Qlik® today announced that Swiss multinational pharmaceutical company Novartis is using Qlik Sense® to drive enterprise-wide data democratization and optimize business processes. Its 30,000 employees have access to over 500 Qlik applications, regardless of location or device, ensuring there is one single source of truth informing decision-making across the entire organization. By enabling the use of data-based insights across all business units, the organization realized savings of over six-figures USD through optimized budget and resource allocations.
The Novartis analytics strategy is designed to further optimize data-driven value creation across the entire company: from saving time and valuable resources, to optimizing processes and identifying new business opportunities. The associative work with the company-wide uniform database, with validated data quality, ensures reliable results that support decisions across every department – from procurement and production to marketing, sales, finance and management.
Novartis chose the Qlik analytics platform because the company values high-performance analysis, optimal data availability, and an intuitive analytics experience that incorporates data from all sources without infrastructure barriers. Data access and availability is controlled within a framework of centrally managed governance. Due to this democratization of all available data, Novartis benefits from a comprehensive self-service operation of the analytics functions, including on mobile devices.
“Data is part of our DNA at Novartis. The challenge we faced was in finding a platform that would allow all departments across the organization to consistently drive value from our data chain,” said Loic Giraud, Business Analytics COE Lead, Novartis. “The role of Qlik in turning our ambitions for data into reality cannot be understated. The platform has not only digitally strengthened, optimized and expanded existing business areas, but is helping to open up new opportunities and is supporting the digital transformation of the entire organization.”
The implementation of the Qlik analytics platform is helping Novartis achieve:
Going forward, Novartis also plans to expand the use of the Qlik analytics platform with location-based data with the help of Qlik GeoAnalytics; combining geographic data with various data sources to improve its existing geo-mapping and increase the value of the map visualizations. The company is also now testing Qlik’s Data Integration solutions to accelerate and ease real time analytics and data unification of sources, such as SAP.
“We are very pleased to support Novartis with our platform and to work together to further their digital transformation,” said Wolfgang Kobek, SVP EMEA at Qlik. “Novartis is benefitting from the real-time and self-service capabilities of Qlik Sense, as well as the reduction of data silos and infrastructure hurdles. This offers them a great advantage in today’s market.”
Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. Qlik provides an end-to-end, real-time data integration and analytics cloud platform to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik does business in more than 100 countries and serves over 38,000 active customers around the world.
© 2021 QlikTech International AB. All rights reserved. All company and/or product names may be trade names, trademarks and/or registered trademarks of the respective owners with which they are associated.
The information provided herein is subject to change without notice. In addition, the development, release and timing of any product or functionality described herein remain at the sole discretion of Qlik and should not be relied upon in making a purchasing decision, nor as a representation, warranty or commitment to deliver specific products or functionality in the future.